L 368899

a selective oxytocin receptor antagonist; structure in first source

Also Known As:

1-(((7,7-dimethyl-2-(2-amino-4-(methylsulfonyl)butyramido)bicyclo(2.2.1)heptan-1-yl)methyl)sulfonyl)-4-(2-methylphenyl)piperazine; L 368,899; L-368,899; L-368899; Butanamide, 2-amino-N-(7,7-dimethyl-1-(((4-(2-methylphenyl)-1-piperazinyl)sulfonyl)methyl)bicyclo(2.2.1)hept-2-yl)-4-(methylsulfonyl)-, (1S-(1alpha,2alpha(R*),4beta))-

Networked: 6 relevant articles (0 outcomes, 3 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Erfanparast, Amir: 1 article (01/2022)
2.	Esmaeilou, Yasin: 1 article (01/2022)
3.	Soltanalinejad-Taghiabad, Farhad: 1 article (01/2022)
4.	Tamaddonfard, Esmaeal: 1 article (01/2022)
5.	Fu, Min: 1 article (01/2021)
6.	Huang, Chao-Lan: 1 article (01/2021)
7.	Li, Chun-Jie: 1 article (01/2021)
8.	Li, Yue-Ling: 1 article (01/2021)
9.	Lin, Jiu: 1 article (01/2021)
10.	Liu, Fei: 1 article (01/2021)

Related Diseases

1.	Neuralgia (Stump Neuralgia) 01/01/2021 - "And the inhibition effect of OXT on the expression of CGRP, IL-1β, and TNFα was abolished by preapplication of OXTR antagonist L-368,899 into the TG.NEW & NOTEWORTHY This study explores the effects of oxytocin receptor (OXTR) in the trigeminal ganglion (TG) on orofacial neuropathic pain. " 01/01/2022 - "In the present study, microinjection effects of oxytocin and L-368,899 (an oxytocin receptor antagonist) into the primary somatosensory cortex (S1) and anterior cingulate cortex (ACC) were investigated on sensory and affective aspects of neuropathic pain. "
2.	Premature Obstetric Labor (Premature Labor) 03/01/1995 - "During the process of evaluating oxytocin receptor antagonists for further development for treatment of preterm labor, in vivo and in vitro drug metabolism studies conducted in rats, dogs, and monkeys contributed to the selection of L-368,899 as the development candidate on the basis of pharmacokinetic and metabolism observations. " 10/01/1997 - "L-368,899 is a potent, orally-active oxytocin antagonist that completed phase I clinical trials for the prevention of preterm labor. " 03/04/1994 - "1-((7,7-Dimethyl-2(S)-(2(S)-amino-4-(methylsulfonyl)butyramido)bicyclo [2.2.1]-heptan-1(S)-yl)methyl)sulfonyl)-4-(2-methylphenyl)piperaz ine (L-368,899): an orally bioavailable, non-peptide oxytocin antagonist with potential utility for managing preterm labor."
3.	Heat Stroke (Heatstroke) 12/05/2019 - "The results showed that OT could not protect against the aforementioned heat stroke responses in rats treated with L-368,899. "
4.	Hypersensitivity (Allergy) 01/01/2021 - "In addition, administration of OXT (50 and 100 μM) into the TG attenuated the mechanical hypersensitivity induced by IANX, which was reversed by pretreatment with L-368,899 (a selective antagonist of OXTR) into the TG. "
5.	Hyperalgesia 01/01/2022 - "In the S1, alone L-368,899 with no effect on aversion increased mechanical allodynia, whereas, in the ACC, this treatment increased both mechanical allodynia and aversion. " 01/01/2022 - "Pre-treatment with L-368,899 prevented oxytocin-induced anti-allodynia and anti-aversion. " 01/01/2022 - "Oxytocin and L-368,899 did not alter mechanical allodynia in intact and sham groups. "

Related Drugs and Biologics

1.	Oxytocin Receptors (Oxytocin Receptor)
2.	Oxytocin (Pitocin)
3.	Peptides (Polypeptides)
4.	salicylhydroxamic acid (SHAM)